Lee Dong-hoon, President of SK Biopharm, Delivers Keynote Speech at US KAPAL Annual Conference

Conference Hosted by the Korea-US Life Science Association
Growth Strategies and Introduction to 'Xcopri'

SK Biopharm announced on the 30th that it participated in the 7th 'KAPAL Annual Conference' hosted by the Korean American Pharmaceutical and Life Sciences Association (KAPAL) at Montgomery College Rockville Campus in Maryland, USA, from the 27th to the 28th (local time).

Lee Dong-hoon, President of SK Biopharm, is delivering the keynote speech at the 7th 'KAPAL Annual Conference' on the 27th.
[Photo by SK Biopharm]

The KAPAL Annual Conference is a conference where experts in life sciences and pharmaceutical health gather to exchange knowledge and experience, foster interaction and cooperation, and nurture young scientists and professionals.

This year’s theme was "Empowering Global Collaboration & Strategy in the Future of Life Science," featuring sessions on funding methods within the US, various global joint research and clinical trials, regulatory approval strategies, and career development.

On the 27th, President Donghoon Lee gave the opening keynote speech, introducing SK Biopharm’s history of new drug development as the first domestic company to directly market new drugs in the US, along with its flagship product, Xcopri (generic name cenobamate). He then explained the sales network and marketing strategies in the US, as well as global partnerships. He also presented future growth strategies to become a balanced big biotech company and the introduction and advancement strategies of innovative technology platforms in three new modality areas.

Following President Lee, Haeyoung Ahn, former Deputy Commissioner of the US Food and Drug Administration (FDA) and currently an outside director of SK Biopharm as well as CEO of AnBio Consulting, shared her experience and information from the FDA through a regulatory strategy session for new drug development.

Byungha Lee, President of KAPAL, said, "It is a great honor to invite SK Biopharm as the keynote speaker," adding, "We hope this will lay the foundation for hosting many joint events with Korean bio companies in the future."

President Donghoon Lee of SK Biopharm stated, "I am pleased to introduce SK Biopharm and have the opportunity to engage with and discuss various topics related to the future of new drug development through this conference," and added, "As a company representing Korea’s new drug business, we will actively exchange and cooperate with experts from both countries and seek roles that contribute to the mutual growth of business and ecosystem."

KAPAL is a non-profit organization based in Washington DC, Maryland, Virginia, and California, where pharmaceutical regulatory agencies such as the FDA and the National Institutes of Health (NIH) are located. It aims to promote Korea’s bio new drug development industry and global expansion and cooperation with the US.

This content was produced with the assistance of AI translation services.